Compound Overview
US peptide-related searches surpassed 10 million per month in early 2026, with GLP-1 class compounds representing the largest share of that volume. For researchers in metabolic science, understanding the mechanistic differences between Tirzepatide and Retatrutide is foundational.
Both are sold as research compounds only. Neither is approved for human use outside of specific FDA-authorized therapeutic contexts. All research applications of these compounds must remain within appropriate laboratory and in vitro study frameworks.
Tirzepatide functions as a dual receptor agonist, acting on both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It was developed as a synthetic peptide mimicking endogenous incretin hormones. Research has explored its effects on insulin secretion, glucagon suppression, gastric emptying, and energy metabolism in animal models and clinical trials.
Retatrutide extends the dual agonism of Tirzepatide by adding glucagon receptor (GCGR) activity. This triple receptor targeting has generated significant research interest for its implications in energy expenditure modeling. The glucagon component, which Tirzepatide lacks, is studied for its potential contribution to hepatic glucose regulation and thermogenesis pathways.
The choice depends on the research protocol. Studies focused on dual incretin signaling typically center on Tirzepatide. Studies exploring the incremental contribution of glucagon receptor engagement — particularly for energy expenditure outcomes — often require Retatrutide. Some research programs source both for comparative protocol design.
Plato Peptides carries both compounds at ≥98% HPLC purity with COA documentation from independent laboratories.